Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.

被引：0
|
作者：
Zheng, Hanke
Yu, Tianzhou
Romley, John
Barzi, Afsaneh
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] City Hope AccessHope, Med Oncol & Therapeut, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23121
引用
收藏
页数：1
相关论文
共 50 条
  • [1] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [2] Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
    Grell, Peter
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Tuskova, Helena
    Buchler, Tomas
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [4] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [6] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] TAS-102 for the treatment of metastatic colorectal cancer
    Salvatore, Lisa
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Loupakis, Fotios
    Falcone, Alfredo
    Masi, Gianluca
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
  • [8] Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)
    Kotani, Daisuke
    Shitara, Kohei
    Fukuoka, Shota
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Yoshino, Takayuki
    ANNALS OF ONCOLOGY, 2015, 26 : 72 - 72
  • [9] A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Bendell, Johanna C.
    Mayer, Robert J.
    Benedetti, Fabio M.
    Rosen, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
12345